| Endometriosis is a chronic and progressive disease that affects approximately 10%of women of reproductive age.Mifepristone,an antiprogestogen,display antiproliferative effects in the endometrium.Evidence suggests that Mifepristone may be used to treat endometriosis without affecting ovarian function and without being associated with bone loss and hypoestrogenism.In this study,mifepristone was capsulated in Biodegradable polyε-caprolactone tubes(0.D:2.5mm) to formulate the implantable implants.In vitro drug release studies revealed a mean release rate of about 9 ug/day from a single 3 cm length of implant for 15 days.After 30 days,the mean release rate reduced to about 5 ug/day and was maintained for over 6 months.In rat experiments,the peak concentrations of mifepristone occurred in all rats at the 7th days and increased in proportion to dose.After 7 days,the Serum levels of mifepristone decreased gradually.14 days after administration,the concentrations of serum mifepristone in all experiment groups showed no significant differences except the rats with 3 pieces of 3.0 cm length of mifepristone-releasing implants.mifepristone-releasing implants produced obvious inhibitory effects on the growth of endometrial explants in rats in dose-dependent.Administration of 1/2,1,2 pieces of 3.0 cm length of mifepristone-releasing implants produced inhibitory effects of 18.6±17.3%,31.5±12.7%and 72.2±12.3%respectively at 1 month.With the dose of 3 pieces of 3.0 cm length of implants given,better inhibitory effects were not observed.There were obvious therapeutic effects of administration of subcutaneous mifepristone-releasing implants on endometriosis and there is a good future.
|
PDF Full Text Request